ArticleLipids in health and disease2026
Impact of altered HDL2b/HDL3 ratio on the function of innate immune cells in sepsis.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSepsis is characterized by dysregulated immunologic reactions to infectious insults, representing a main cause of death for seriously ill patients. Studies have demonstrated correlations between rapidly declined high-density lipoprotein (HDL) levels during initial sepsis phases with increased mortality and adverse clinical outcomes. Furthermore, HDL subcomponents, specifically HDL2b and HDL3, undergo significant alterations in composition in sepsis patients. This article was aimed at investigating the effects of alterations in the ratio of HDL2b to HDL3 (HDL2b/3) on the function of human umbilical vein endothelial cells (HUVECs) and monocyte-macrophages (THP-1 and RAW264.7 cells).
methodsPlasma samples were collected from 10 sepsis patients and 10 healthy controls. High-density lipoprotein (HDL) subclasses (HDL2b and HDL3) were separated and quantified using fast protein liquid chromatography (FPLC) and ELISA. Human monocytic leukemia cells (THP-1) and human umbilical vein endothelial cells (HUVECs) were co-incubated with different reconstituted ratios of HDL2b/3 under lipopolysaccharide (LPS) stimulation to evaluate cell viability, inflammatory cytokine expression, angiogenesis, and cell migration.
resultsOur results showcase evidently reduced HDL2b/3 ratios for the sepsis group compared with their non-sepsis counterparts. Notably, HDL2b/3 from both groups attenuated the gene expression of lipopolysaccharide-stimulated inflammatory factors (interleukin-1β and tumor necrosis factor-α) within THP-1 cells, RAW264.7 cells, and HUVECs. Additionally, HDL2b/3 mitigated the detrimental effects of LPS on THP-1 and RAW264.7 cells.
conclusionThis research highlights that altered HDL subcomponent ratios can potentially modulate inflammation and cellular responses during sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.